Clinical Trials
27 trialsTAPUR
American Society of Clinical Oncology
MIRAGE
Istituto Oncologico Veneto IRCCS
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Peking University Cancer Hospital & Institute
Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.
Sun Yat-sen University
MegaMOST
Centre Leon Berard
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
Zhejiang Hisun Pharmaceutical Co. Ltd.
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer
National Cancer Institute, Naples
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Case Comprehensive Cancer Center
LEAF-02
Fudan University
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Fudan University
x-МАР
Pavlov First Saint Petersburg State Medical University
The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
Shanghai Changzheng Hospital
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Humanity & Health Medical Group Limited
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
Fudan University
THYMI
Beijing Friendship Hospital
CARE
Centre Hospitalier Universitaire de Besancon
SLOT
Fudan University
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
FINPROVE
Helsinki University Central Hospital
DRUP
The Netherlands Cancer Institute
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
Peking University Cancer Hospital & Institute
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade
Peking University Cancer Hospital & Institute
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
Fudan University